LXEO · Lexeo Therapeutics, Inc.

$4.55 -0.14 (-2.99%) At close · Jul 20

Market Cap

$357.27M

78.52M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
R. Nolan Townsend	CEO	$632,700	—	$1,493,488	$1,165,982	$347,985	$10,785	$3,650,940
Jenny R. Robertson	Chief Legal Officer	$459,600	—	$485,613	$407,444	$183,840	$609,386	$2,145,883
Louis Tamayo	CFO	$181,818	—	$215,550	$1,066,013	$197,760	$4,774	$1,665,915

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
R. Nolan Townsend	CEO	$600,000	—	$633,500	$2,833,754	$297,000	$10,994	$4,375,248
Jose Manuel Otero	Chief Operating Officer	$268,854	—	$568,438	$2,545,286	$165,300	$7,590	$3,555,468
Eric Adler	Chief Medical Officer and Head of Research	$468,939	—	$456,875	$2,044,217	$171,000	$21,503	$3,162,534
Jenny R. Robertson	Chief Legal Officer	$436,500	—	$343,900	$1,532,228	$160,632	$11,850	$2,485,110
Louis Tamayo	CFO	—	—	—	—	—	—	—

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Eric Adler	Chief Medical Officer and Head of Research	$296,500	$234,750	—	$2,419,424	$80,750	$11,400	$3,042,824
R. Nolan Townsend	CEO	$508,000	—	—	$872,883	$347,880	$8,455	$1,737,218
Jose Manuel Otero	Chief Operating Officer	—	—	—	—	—	—	—

Executive changes

Person	Role	Change	Effective	Filed
Dr. Laura Sepp-Lorenzino	Director	Appointed	2026-04-28	2026-04-30

Key facts CIK 1907108 CUSIP 52886X107 13F (30d) 11 filings 10 filers Visit website Investor relations